Cannabidiol - GW Pharmaceuticals

Drug Profile

Cannabidiol - GW Pharmaceuticals

Alternative Names: CBD - GW Pharmaceuticals; Epidiolex; GW-42003; GWP-42003; GWP-42003-P

Latest Information Update: 27 Jun 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GW Pharmaceuticals
  • Developer GW Pharmaceuticals; University of Alabama at Birmingham; University of Utah
  • Class Analgesics; Anti-inflammatories; Antiepileptic drugs; Antipsoriatics; Antipsychotics; Antirheumatics; Anxiolytics; Cannabinoids; Cyclohexenes; Drug withdrawal therapies; Heart failure therapies; Muscle relaxants; Neuroprotectants; Obesity therapies; Skin disorder therapies; Small molecules
  • Mechanism of Action Antioxidants; Cannabinoid receptor CB1 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Lennox-Gastaut syndrome; Dravet syndrome; Infantile spasms; Cerebral ischaemia; Tuberous sclerosis
  • New Molecular Entity No

Highest Development Phases

  • Registered Dravet syndrome; Lennox-Gastaut syndrome
  • Phase III Infantile spasms; Tuberous sclerosis
  • Phase II Epilepsy; Opioid abuse; Parkinson's disease; Schizophrenia
  • Phase I Cerebral ischaemia
  • Preclinical Duchenne muscular dystrophy; Ovarian cancer
  • Discontinued Dyslipidaemias; Non-alcoholic fatty liver disease; Type 2 diabetes mellitus; Ulcerative colitis

Most Recent Events

  • 07 Aug 2018 GW Pharmaceuticals decides to expand target indications for cannabidiol to Autism, and intends to submit IND for pivotal Rett Syndrome trial in Q4 2018
  • 25 Jun 2018 Registered for Dravet syndrome (Adjunctive treatment, In adolescents, In children, In adults) in USA (PO) - First global approval
  • 25 Jun 2018 Registered for Lennox-Gastaut syndrome (Adjunctive treatment, In adolescents, In children, In adults) in USA (PO) - First global approval
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top